Oncolytics Biotech, Inc (NASDAQ: ONCY)’s stock price has gone rise by 19.60 in comparison to its previous close of 0.74, however, the company has experienced a 6.19% increase in its stock price over the last five trading days. prnewswire.com reported 2024-12-18 that SAN DIEGO and CALGARY, AB, Dec. 18, 2024 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the presentation of two data sets through two abstracts showcasing pelareorep’s potential in difficult-to-treat gastrointestinal cancers were accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco January 23-25, 2025. Tom Heineman, M.D.
Is It Worth Investing in Oncolytics Biotech, Inc (NASDAQ: ONCY) Right Now?
ONCY has 36-month beta value of 1.34. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ONCY is 75.99M, and currently, short sellers hold a 3.49% ratio of that float. The average trading volume of ONCY on December 20, 2024 was 520.24K shares.
ONCY’s Market Performance
The stock of Oncolytics Biotech, Inc (ONCY) has seen a 6.19% increase in the past week, with a -16.28% drop in the past month, and a -3.95% fall in the past quarter. The volatility ratio for the week is 10.88%, and the volatility levels for the past 30 days are at 6.67% for ONCY. The simple moving average for the past 20 days is 1.02% for ONCY’s stock, with a -14.68% simple moving average for the past 200 days.
Analysts’ Opinion of ONCY
Many brokerage firms have already submitted their reports for ONCY stocks, with Maxim Group repeating the rating for ONCY by listing it as a “Buy.” The predicted price for ONCY in the upcoming period, according to Maxim Group is $3 based on the research report published on October 06, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ONCY reach a price target of $15. The rating they have provided for ONCY stocks is “Buy” according to the report published on February 17th, 2021.
ONCY Trading at -15.21% from the 50-Day Moving Average
After a stumble in the market that brought ONCY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.00% of loss for the given period.
Volatility was left at 6.67%, however, over the last 30 days, the volatility rate increased by 10.88%, as shares sank -11.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.26% lower at present.
During the last 5 trading sessions, ONCY rose by +6.19%, which changed the moving average for the period of 200-days by -14.67% in comparison to the 20-day moving average, which settled at $0.8783. In addition, Oncolytics Biotech, Inc saw -34.27% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ONCY
The total capital return value is set at -2.13. Equity return is now at value -144.22, with -78.05 for asset returns.
Currently, EBITDA for the company is -33.71 million with net debt to EBITDA at 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.99.
Conclusion
To put it simply, Oncolytics Biotech, Inc (ONCY) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
